-- 2026年4月28日，董事、董事長兼執行長Sanj K Patel出售了Kiniksa Pharmaceuticals International (KNSA)的508,339股股票，套現26,415,228美元。根據向美國證券交易委員會（SEC）提交的4號表格文件，Patel目前持有該公司237,763股A類普通股，另有237,763股為間接控制。 SEC文件連結： https://www.sec.gov/Archives/edgar/data/1730430/000153221826000006/xslF345X05/form4-04302026_100400.xml
Related Articles
Asia
Yamato's Profit Plunges Down 64% in Fiscal Year 2025
Yamato (TYO:1967) profit attributable to owners of the parent plunged 64% to 13.7 billion yen in fiscal year 2025 from 37.9 billion yen a year earlier.The Japanese general contractor's basic earnings per share decreased to 43.07 yen from 111.87 yen a year ago, according to a Tokyo bourse filing on Thursday.Operating revenue increased 5.8% to 1.865 trillion yen for the year ended March 31, from 1.762 trillion yen in the previous fiscal year.Yamato declared a final dividend of 23 yen per share.For fiscal year 2026, the company expects attributable profit of 24 billion yen, basic EPS of 75.79 yen and operating revenue of 1.920 trillion yen.Shares of Yamato rose more than 3% at market close.
$TYO:1967
Asia
Mirae Asset Securities Upgrades Mphasis to Buy from Add; Price Target is INR2,690
Mphasis (NSE:MPHASIS, BOM:526299) has an average rating of overweight and mean price target of 2,716.19 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$BOM:526299$NSE:MPHASIS
Mining & Metals
Real Matters Q2 Consolidated Revenues of US$47.2M, up 27% YoY
$REAL.TO